Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    AB8939

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Ab8939, Ab-8939, 1-(4-(2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl)-phenyl)-imidazolidin-2-one, 2-imidazolidinone, 1-(4-(2-((5-(ethoxymethyl)-2-methylphenyl)amino)-5-oxazolyl)phenyl)-, 1974336-09-8, Unii-reu6l9a46j
    Molecular Formula
    C22H24N4O3
    Molecular Weight
    392.5  g/mol
    InChI Key
    ZBAFYGYLXHEICJ-UHFFFAOYSA-N
    FDA UNII
    REU6L9A46J
    Tubulin Polymerization Inhibitor AB8939 is a small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Upon administration, tubulin polymerization inhibitor AB8939 binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. Additionally, unlike similar agents of this class, AB8939 may be able to circumvent some drug resistance mechanisms.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]imidazolidin-2-one
    2.1.2 InChI
    InChI=1S/C22H24N4O3/c1-3-28-14-16-5-4-15(2)19(12-16)25-21-24-13-20(29-21)17-6-8-18(9-7-17)26-11-10-23-22(26)27/h4-9,12-13H,3,10-11,14H2,1-2H3,(H,23,27)(H,24,25)
    2.1.3 InChI Key
    ZBAFYGYLXHEICJ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCOCC1=CC(=C(C=C1)C)NC2=NC=C(O2)C3=CC=C(C=C3)N4CCNC4=O
    2.2 Other Identifiers
    2.2.1 UNII
    REU6L9A46J
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Ab8939

    2. Ab-8939

    3. 1-(4-(2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl)-phenyl)-imidazolidin-2-one

    4. 2-imidazolidinone, 1-(4-(2-((5-(ethoxymethyl)-2-methylphenyl)amino)-5-oxazolyl)phenyl)-

    5. 1974336-09-8

    6. Unii-reu6l9a46j

    7. Schembl17965581

    2.4 Create Date
    2016-12-08
    3 Chemical and Physical Properties
    Molecular Weight 392.5 g/mol
    Molecular Formula C22H24N4O3
    XLogP33.2
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count7
    Exact Mass392.18484064 g/mol
    Monoisotopic Mass392.18484064 g/mol
    Topological Polar Surface Area79.6 Ų
    Heavy Atom Count29
    Formal Charge0
    Complexity540
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1